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Abstract
Background: Variability in dosing and costs of biologics among patients with rheumatoid arthritis
(RA) is of interest to healthcare descision-makers. We examined dosing and costs among RA
patients newly treated with infliximab or etanercept under conditions of typical clinical practice.
Methods: Integrated pharmacy and medical claims data were obtained from 61 U.S. health plans.
RA patients newly treated with infliximab or etanercept between July 1999–June 2002 were
selected. A maintenance number of infliximab vials was determined after the "loading period" (2–3
infusions); those with ≥ 2 occurrences of an increase in vials or an interval between infusions of
<49 days were considered to have had escalated. For etanercept patients, escalation was based on
≥ 2 instances of increased average daily dose. Multiple logistic regression analyses were conducted
to assess variables associated with dose escalation. RA-related costs at one year post-initiation also
were examined; comparisons were made using generalized linear models.
Results: A total of 1,548 patients were identified (n = 598 and 950 for infliximab and etanercept
respectively). Infliximab recipients were somewhat older (50.5 vs. 46.6 years for etanercept).
Nearly 60% of infliximab patients increased their dose at one year, compared to 18% for
etanercept. Infliximab patients who escalated dose incurred a 25% increase in mean one-year costs
($20,915 vs. $16,713 for no increase; p < 0.0001). Costs among etanercept patients did not
substantially differ based on dose escalation ($14,482 vs. $13,866 respectively).
Conclusions: Infliximab is associated with higher rates of dose escalation relative to etanercept,
which contributes to substantially higher one-year medical costs.
Background
Rheumatoid arthritis is a costly and debilitating autoim-
mune disorder that is characterized by joint pain, stiff-
ness, and impaired functionality. Symptoms arise from
the inflammation and degradation of the synovial mem-
brane, causing progressive disability in joint function [1].
As the disease progresses, patients require more frequent
invasive procedures (e.g., joint injections, synovectomy)
as well as the eventual replacement of affected joints. Con-
sequently, the economic costs of RA are considerable, as
the estimated direct and indirect costs of related care in
the US totals $19 billion annually [2].
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Because there is no known cure for RA, the goal of therapy
is to treat the disease's symptomatology while attempting
to slow or halt its overall progression. Pharmacotherapy is
the cornerstone of treatment where symptoms may be
treated with various combinations of nonsteroidal anti-
inflammatory drugs (NSAIDs), corticosteroids, and nar-
cotic analgesics. In addition, disease-modifying antirheu-
matic drugs (DMARDs) are sometimes administered in an
effort to alter the disease's progression. The effectiveness
of DMARDs, however, is offset by the high levels of toxic-
ity experienced by some patients taking these medica-
tions, and is problematic for long-term therapy [3].
In addition to the use of various DMARDs either alone or
in combination with other therapies, several new
DMARDs have recently been introduced for the treatment
of RA. These include two biologic agents, etanercept
(Enbrel®, Amgen, Inc./Wyeth, Inc., Thousand Oaks, CA
and St. David's, PA) and infliximab (Remicade®, Centocor
Inc., Malvern, PA) which provide anti-rheumatic activity
by inhibiting tumor necrosis factor (TNF), another impor-
tant mediator of an inflammatory response. The use of
such agents in combination with the DMARD methotrex-
ate has been shown to be clinically superior to methotrex-
ate alone in controlled clinical trials [4-12].
The results of recent observational studies examining the
effectiveness of infliximab indicate that increased or more
frequent dosing (i.e., beyond what is mentioned in the
product labeling) may provide additional benefits for
patients with rheumatoid arthritis [13,14]. However, the
costs associated with use of biologic agents is already far
greater than other DMARDs. Therefore, economic consid-
erations may impact physicians' willingness to prescribe
as well as commercial insurers' placement of biologic
agents in the sequence of care.
Given the wide disparity in costs between therapy alterna-
tives and the potential impact of dose escalation on these
costs, it is essential to examine the total costs of RA-related
care associated with each form of therapy from a perspec-
tive of typical U.S. clinical practice. In this study, the direct
costs of RA-related care were estimated on an annual basis
after initial treatment with anti-TNF biologics. Resource
utilization and cost estimates were also stratified by dos-
ing status (increase in dose during follow-up vs. no
increase), using retrospective claims data from commer-
cial insurers in the US.
Methods
Data source
Medical and pharmaceutical service claims were obtained
from the PharMetrics Patient-Centric Database, and
spanned the period from January 1999 to June 2002. At
the time of this study, the database contained fully adju-
dicated service claims from 61 health plans across the US.
Inpatient and outpatient diagnoses (ICD-9-CM format)
and procedures (CPT-4 and HCPCS formats), as well as
standard and mail order prescription records, are included
in the data set. Reimbursed payments and charged
amounts are available for all services rendered, as well as
dates of service for all claims. Additional data elements
include demographic variables (e.g., age, gender, geo-
graphic region), product type (e.g., HMO, PPO), payor
type (e.g., commercial, self-pay), provider specialty, and
start and stop dates for plan enrollment. All patients who
met the sample selection criteria specified below were
included in the analyses.
Sample selection
Patients with a diagnosis of rheumatoid arthritis (ICD-9-
CM 714.XX) who newly started on infliximab or etaner-
cept between July 1999 and June 2001 were initially
selected for inclusion in the study sample. A hierarchical
procedure was then implemented to stratify patients into
treatment cohorts according to their first utilization of a
particular medication at a specific point in time. For
example, a patient initially receiving infliximab and later
receiving etanercept would be classified as an "infliximab"
patient for the duration of the study period. An index date
for each therapy was established based on the first occur-
rence of a claim. Patients with no claims activity for the
index therapy for six months prior to the index date were
deemed "newly started".
Those patients not continuously enrolled during the six-
month pretreatment and 12-month follow-up periods
were excluded from all analyses. Additionally, patients
must have had at least five infusions or prescriptions for
their index medication. Patients 65 and older who were
not enrolled in a Medicare "risk" plan (i.e., a commercial
plan that agrees to undertake full financial risk for a Medi-
care beneficiary) were excluded from each of the analyses,
as such patients may not have had fully visible utilization
and cost values due to coordination of medical benefits.
All medical and pharmaceutical claims spanning the
period January 1, 1999 to June 30, 2002 were then
extracted for eligible patients in the data set.
Measures
The primary measures of interest in this evaluation were
the frequency and economic impact of an escalation in
biologic dose. Dose escalation was assessed for patients
new to infliximab and etanercept during the study period
described above. Infliximab and etanercept doses
reported at the third infusion/prescription respectively
were considered to be the maintenance dose levels. Subse-
quent utilization was then examined to determine dose
escalation. Dose escalation for patients initiating inflixi-
mab was based on at the presence of least two occurrencesBMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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of an increase in the number of vials reported on the infu-
sion claim. The standard period (as indicated on the pre-
scribing information for infliximab) between infusions
following the third infusion is eight weeks. Therefore,
patients with two infusions within seven weeks on two or
more occasions were also considered to have an increase
in dose. Dose escalation for patients initiating etanercept
therapy was determined according to a change in the aver-
age daily dose (expressed in terms of mg per day); average
daily dose was calculated based on data from pharmacy
claims, using the following formula:
metric strength(25 mg)*quantity dispensed (in vials)/
days supplied
Patients having two or more prescriptions with a higher
average daily dose than that reported on their mainte-
nance dose were considered to have an increase in dose.
Dose escalation results were reported on an overall basis
and stratified by age (<18, 18–34, 35–44, 45–54, 55–64,
and 65 years and over respectively), geographic region
(East, South, Midwest, West), calendar year of biologic
therapy initiation (1999, 2000, or 2001), and quartile of
pre-index RA-related costs.
In addition to dose escalation, the demographic and clin-
ical characteristics of the sample also were assessed and
stratified among patients who did and did not escalate
their dose. Characteristics of interest included age, gender,
health plan type, geographic region, physician specialty as
of the index date, presence of selected pre-index medica-
tions, procedures, and comorbid diagnoses, co-diagnosis
of Crohn's disease, and pre-index total (i.e., RA-related
and unrelated) healthcare costs.
During follow-up, the numbers of prescriptions or infu-
sions of biologic therapy were tracked, as were the costs of
all appropriate medical interventions, inpatient, outpa-
tient, and pharmacy services. Costs were tallied for both
RA-related and unrelated services and medications. Costs
were deemed to be RA-related based on the presence of a
relevant diagnosis, medication claim, or procedure (See
Appendix 'Additional file 1' for ICD-9-CM, CPT-4, and
GPI drug codes).
Analyses
Based on the sample described above, a series of analyses
were conducted as follows:
1. Dose Escalation – compared the rate of dose escalation
at one year among patients initiating etanercept or inflix-
imab therapies;
2.  Predictive Model for Dose Escalation – identified RA
patients most likely to experience an increase in dose at
one year, isolating specific medical, pharmaceutical and
demographic characteristics that served as predictors for
patients increasing drug utilization; and
3. Comparison of Annual Costs – compared costs between
etanercept and infliximab stratified by whether or not the
patient escalated their dose.
The proportion of patients escalating dose was compared
between patients receiving etanercept and infliximab
using a chi-square test or Fisher's Exact Test (for cell sizes
less than five). In addition, a multiple logistic regression
model was applied to identify characteristics that were
most predictive of patients experiencing an escalation in
dose (including the index biologic therapy). The selection
of predictors for inclusion in the models began with a uni-
variate analysis of each variable to determine the fre-
quency of the observations associated with each treatment
cohort. An initial model run was performed using the fol-
lowing variables: age group, gender, region, biologic ther-
apy group, plan type, prescribing specialty, RA-related
costs during the six month pre-index period, non-RA
related costs during the pre-index period, maintenance
dose, dummy variables (1 = present, 0 = absent) for the
receipt of other RA related medications during the pre-
index period, and selected comorbidities. A stepwise
method was employed to produce the final model specifi-
cation using an "entry" level of α = 0.15 and a "stay" level
of α = 0.05.
The amount of costs (reimbursed amounts paid by health
plans) for all services previously described were calculated
on an annual per patient basis for each cohort. Total RA-
related, unrelated, and overall costs during the one-year
follow-up period were compared controlling for differ-
ences in age, gender, pre-index RA related costs and other
appropriate variables between the cohorts. A generalized
linear model using a gamma distribution was used to con-
trol for these differences.
Results
Patient demographics and clinical characteristics
Clinical and demographic characteristics of the study sam-
ple (N = 1,548) are presented in Table 1. Overall, approx-
imately one-third of patients (31%) were aged 55 or older.
However, infliximab use was more concentrated among
older patients, as 37% of patients on this therapy were 55
or older; compared to 27% of etanercept patients. Not sur-
prisingly, females had a greater representation than males
in the study sample, accounting for nearly three quarters
of the study population (74%). Rates were similar for the
infliximab and etanercept groups respectively (76.4% and
72.1%). Most patients in the sample were members of an
HMO or PPO product; however, the use of infliximab was
much lower in the HMO group compared to etanerceptBMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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(30% vs. 45% respectively) and substantially higher
among PPO patients (49% vs. 35% respectively).
The use of other RA-related medications prior to biologic
use differed numerically by treatment group. NSAIDs
were used more frequently by etanercept users relative to
infliximab (42% vs. 26% respectively), as were Cox-II
inhibitors (35% vs. 27% respectively) and leflunomide
(26% vs. 19% respectively). The rate of pretreatment
methotrexate use was similar among the etanercept and
infliximab groups (55% and 56%).
Utilization of joint aspiration procedures was numerically
higher during the pre-index period for patients in the inf-
liximab group relative to the etanercept sample (35% and
28% respectively). Additionally, pre-index RA related
costs also were somewhat higher among infliximab
patients ($3,916 vs. $3,585).
Dose escalation
Patients who initiated infliximab therapy experienced sig-
nificantly higher rates of dose escalation during the first
year of follow-up relative to patients who were initiated
on etanercept (58% vs. 18%; p < 0.001) (Table 2). When
stratified by pre-index costs, patients initiating infliximab
therapy had consistently higher rates of escalation relative
to patients on etanercept therapy, although the rate of
dose escalation generally increased with pre-index costs;
the rate of escalation at one year for patients with the low-
est pre-index costs was 50% for the infliximab cohort
compared to 17% for patients initiating etanercept (p <
0.001); corresponding rates were 62% and 21% in the
highest cost group (p < 0.001). When stratified by year of
therapy initiation, age, and geographic region, rates of
escalation were significantly higher among patients initi-
ating infliximab therapy relative to the etanercept cohort
across all groups. The rate of escalation increased by cal-
endar year for patients receiving infliximab, but declined
among etanercept users. Interestingly, while the rate of
dose escalation increased with increasing age in the
etanercept group, this rate declined in the infliximab
group as age increased (beyond age 35); for example,
Table 1: Demographic/Clinical Characteristics (6 month pre-
period)
Characteristic Infliximab
(N = 598)
Etanercept
(N = 950)
Age (%)
< 18 0.2 4.1
18 – 34 7.0 8.7
35 – 44 19.9 23.3
45 – 54 35.8 37.2
55 – 64 32.4 25.1
65 + 4.7 1.7
Age
Mean 50.5 46.6
SE 0.4 0.4
Min 16 2
Max 80 88
Gender (% female) 76.4 72.1
Plan Type (%)
HMO 29.8 44.8
PPO 48.7 34.5
POS 12.5 16.3
Indemnity 7.5 2.6
Other 1.5 1.7
Geographic Region (%)
East 8.7 15.7
South 45.0 15.9
Midwest 38.8 57.4
West 7.5 11.1
Physician Specialty (%)
FP/GP 6.4 3.4
Internal Medicine 3.5 3.8
Rheumatology 52.7 64.1
Other 27.6 18.8
Unknown 9.9 9.9
Infusions/Rxs (Infliximab/Etanercept)
Mean 7.0 10.4
Median 7.5 11.0
SD 2.1 3.8
Pre-index Therapies (%)
NSAID 26.3 41.6
Cox-II 27.1 34.5
Other Misc. Anti-inflammatory 1.3 3.2
Gold Compound 2.7 3.3
Methotrexate 56.5 55.2
Leflunomide 19.4 25.9
Other DMARD 20.7 26.6
Other RA related therapy 74.9 78.8
Pre-index Medical Diagnoses (%)
Osteoporosis 9.2 7.5
Depression 3.8 3.2
Selected Pre-index Procedures (%)
Joint Aspiration/Injection Procedures 34.6 27.7
Synovectomy 0.7 0.7
Arthroplasty 1.5 0.8
Arthrodesis 0.7 0.9
Arthroscopy 0.8 1.4
Liver Function Tests 42.5 54.5
Urinalysis 31.3 33.8
Hematologic/Serologic Tests 81.3 75.8
Bone/Joint Imaging 33.8 31.5
Centesis Procedures 24.1 20.9
Upper Respiratory Infections 5.7 5.8
Chest X-ray 21.4 17.3
Pre-index Total Healthcare Costs ($)
Mean 3,916.40 3,585.11
SE 225.46 252.39
Min 60.23 0.00
Max 47,306.12 178,388.26
Table 1: Demographic/Clinical Characteristics (6 month pre-
period) (Continued)BMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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66.4% of those aged 35–44 in the infliximab group
increased their dose, versus 39.3% in patients aged 65 and
older. Finally, rates of dose escalation varied considerably
by region, with the highest rates observed in the South
and Midwest.
Predictive model for dose escalation
Modeled dose escalation results for patients who initiated
infliximab or etanercept therapy are presented in Table 3.
The type of biologic therapy was by far the most signifi-
cant predictor of dose escalation, as patients starting inf-
liximab were over 6 times more likely to increase dose
than patients starting on etanercept (Transformed Odds
Ratio [OR] = 6.38; p < 0.0001). Patients who were mem-
bers of an HMO were less likely to have an increase in
dose than those who did not. RA patients with a listed
comorbid diagnosis of Crohn's disease were less likely to
escalate dose (OR = 0.48; p = 0.0477) than those without,
while patients utilizing Cox II therapy were significantly
more likely to experience an increase in dose over the
course of the year (OR = 1.36; p = 0.0175). Patients in the
West were much less likely to experience an increase in
dose. Patients in the Northeast were 1.92 times more
likely to increase dose (p = 0.0215), while patients in the
South and Midwest were 1.87 and 1.89 times more likely
to dose escalate (p = 0.0102 and 0.0063 respectively). Age
and gender were not significant predictors of dose escala-
tion, although the likelihood of dose escalation increased
by 4% with every additional $1,000 of RA-related pre-
treatment costs.
In an effort to better understand the factors associated
with infliximab dose escalation, an additional model was
conducted among patients initiating infliximab only.
Results are presented in Table 4. In this model, patients
who belonged to an HMO were significantly less likely to
have an increase in dose at one year relative to patients
with other coverage (OR = 0.68; p = 0.0372). Patients uti-
lizing methotrexate during pretreatment were more likely
to escalate dose than those without (OR = 1.48; p =
0.0216). There was a trend towards significance in terms
of an age effect, as infliximab users between the ages of
35–44 were more likely to escalate dose relative to
younger patients (OR = 1.94; p = 0.0682).
Comparison of annual costs
Overall, costs for patients initiating infliximab therapy
were numerically higher than for patients in the etaner-
cept group ($19,144 vs. $13,977). Much of the cost differ-
ence was due to the difference in drug costs ($13,470 vs.
Table 2: Percent of Patients with an Increase in Dose After One Year
Infliximab Etanercept
Patients with 3+
infusions
Pct with an increase
in dose
Patients with 3+
infusions
Pct with an increase
in dose
p-value
Overall 598 57.9% 950 18.1% <0.001
by Pre-period RA Costs
Quartile 1 – $0 to $502.89 157 49.7% 230 16.5% <0.001
Quartile 2 – $502.90 to $975 157 62.4% 230 18.7% <0.001
Quartile 3 – $975.15 to $176 135 57.8% 252 15.9% <0.001
Quartile 4 – $1766.22 + 149 61.7% 238 21.4% <0.001
by Year
1999* 0 0.0% 196 22.4% <0.001
2000 309 53.1% 602 17.9% <0.001
2001 289 63.0% 152 13.2% <0.001
by Region
East 52 53.8% 149 20.1% <0.001
South 269 60.2% 151 17.2% <0.001
Midwest 232 57.3% 545 19.4% <0.001
West 45 51.1% 105 9.5% <0.001
by Age Group
< 18 Years 1 100.0% 39 33.3% <0.001
18 – 34 Years 42 50.0% 83 14.5% <0.001
35 – 44 Years 119 66.4% 221 16.7% <0.001
45 – 54 Years 214 60.3% 353 17.3% <0.001
55 – 64 Years 194 54.1% 238 18.9% <0.001
65 + Years 28 39.3% 16 25.0% <0.001
*Infliximab dosing for RA was not detectable via HCPCS code until June of 2000BMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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$10,159 respectively). In addition, infliximab patients
had higher costs for physician management visits ($691
vs. $381), ancillary services ($1,511 vs. $866), and hospi-
talizations ($2,277 vs. $1,322). Use of alternative biologic
therapy (i.e., use of etanercept in a patient starting on inf-
liximab and vice versa) was minimal, as illustrated by
extremely low average annual costs for these alternative
strategies.
Average annual RA-related, unrelated, and total costs are
also stratified by whether patients underwent dose escala-
tion in Table 5. Patients in the infliximab group who expe-
rienced an increase in dose had significantly higher RA-
related costs relative to those who remained at mainte-
nance levels ($20,915 vs. $16,713; p < 0.0001). This dif-
ference was primarily manifested in lower pharmacy costs
for patients not escalating dose; for example, annual inf-
liximab costs were 60% higher for patients escalating dose
($15,998 vs. $10,000; p < 0.001). Ancillary costs were also
higher for patients with an increase in dose ($1,601 vs.
$1,387). However, RA-related hospitalization costs were
lower for patients who had an increase in dose ($1,516 vs.
$3,323).
Discussion
In an effort to better understand the differences in dosing
patterns and costs among RA patients on biologic therapy,
a retrospective analysis of pharmacy and medical claims
for patients new to biologic therapy was undertaken. Dos-
ing frequency and quantity was examined, as were RA-
related costs at one year after therapy initiation.
Dosing guidelines suggest that etanercept patients receive
two 25 mg vials a week; the use of higher doses has not
been studied. The recommended dosing for infliximab is
3 mg/kg of body weight for the first dose, and then at two
Table 3: Dose Escalation Regression Estimates – Inflixim ab and Etanercept Dependent Variables (Increase in dose for Inflixim ab or 
Etanercept 1 = yes, 0 = no)
Parameter Level Estimate Odds-Ratio Transformed Odds 
Ratio
Conditional 
Probability
p-value
Intercept -0.3129 0.73 n.a. n.a. 0.1702
HMO Yes -0.2246 0.80 1.00 0.37 0.0826
No 0.0000 1.00 1.25 0.42
Treatment Inflixim ab 0.0000 1.00 6.38 0.42
Etanercept -1.8529 0.16 1.00 0.10 <.0001
Region West 0.0000 1.00 1.00 0.42
Northeast 0.6505 1.92 1.92 0.58 0.0215
Midwest 0.6382 1.89 1.89 0.58 0.0063
South 0.6252 1.87 1.87 0.58 0.0102
Pre-Period Non RA 
Related Costs ('000s)
Yes 0.0350 1.04 1.04 0.43 0.0185
No 1.00 1.00 0.42
Crohn's Disease Yes -0.7328 0.48 1.00 0.26 0.0477
No 0.0000 1.00 2.08 0.42
Cox-IIs Yes 0.3064 1.36 1.36 0.50 0.0175
No 0.0000 1.00 1.00 0.42
Table 4: Dose Escalation Regression Estimates – Inflixim ab Dependent Variables (Increase in dose for Inflixim ab 1 = yes, 0 = no)
Parameter Level Estimate Odds-Ratio Conditional Probability p-value
Intercept -0.0732 0.93 n.a. 0.8209
Age Group
0–34 0.0000 1.00 0.48
34–54 0.6639 1.94 0.64 0.0682
45–54 0.3808 1.46 0.58 0.2594
55+ 0.0648 1.07 0.50 0.8469
HMO HMO -0.3810 0.68 0.39 0.0372
Pre-Index Therapy Methotrexate 0.3900 1.48 0.58 0.0216BMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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and six weeks and every eight weeks thereafter. Patients
experiencing an inadequate response may increase dose to
10 mg/kg; or they may receive treatment as frequently as
every four weeks [15]. The flexibility in these guidelines
appears to be necessary, as infliximab patients in our
study were much more likely to experience a dose escala-
tion than patients on etanercept. There also appeared to
be a strong relationship between the utilization of Cox-II
inhibitors as well as pretreatment RA-related costs and
dose escalation, indicating that disease severity may play
a role in the decision to increase dose. Recent evidence
suggests, however, that the relationship between dose
escalation and disease activity is nonlinear. In a recent
examination of infliximab and etanercept use in Sweden,
improvement in disease activity levels following inflixi-
mab dose escalation was similar to that observed among
infliximab patients not escalating dose as well as etaner-
cept recipients [16].
Lastly and most importantly, differences in RA-related
cost among patients new to infliximab and etanercept
therapy ($19,144 vs. $13,977) were manifested mainly in
the treatment costs ($13,470 vs. $10,159). Management
and ancillary services accounted for most of the remaining
difference. The difference in treatment costs may be attrib-
uted to the higher rate of dose escalation among the inf-
liximab group. These patients had treatment expenses that
were ~60% higher than patients who did not dose escalate
($15,998 vs. $10,000), while infliximab patients who did
not dose escalate had costs similar to patients in the
etanercept group. There was little difference in drug ther-
apy costs among etanercept patients who experienced an
increase in dose and those with no change ($10,427 vs.
$10,100). These findings highlight the differences in treat-
ment patterns and associated costs among patients new to
etanercept and infliximab.
Our study was subject to some important limitations.
First, as this was a retrospective analysis of claims data,
results were based on amounts billed to health plans. As a
result, the unit of measurement for infliximab is billed
whole vials. For example, if 1.2 vials were administered to
a patient, 2 vials would be billed to the health plan. There-
fore, these results may not reflect the true amount of inf-
liximab utilized and may in fact under- or overstate the
rate of dose escalation – for example, a patient who
increases from 1.2 to 1.7 vials will be shown to have uti-
lized 2 vials in both instances; in contrast, a patient mov-
ing from 1.9 to 2.1 vials will appear as having moved from
2 to 3 vials.
In addition, information regarding body mass and/or
patient weight was not available. As stated above, inflixi-
mab dosing levels may range from 3 mg/kg to 10 mg/kg.
Dosing changes resulting from weight changes alone were
therefore undetectable. Also, one method of estimation of
Table 5: Total Costs of Care for RA Patients at One Year
Infliximab N = 598 Etanercept N = 950 Infliximab: Dose 
Escalation vs. No 
Escalation (p-value)
Dose Escalation No Escalation Dose Escalation No Escalation
N = 346 N = 252 N = 172 N = 778
Measure Cost per patient (mean, SE), $
RA Related Costs $20,914.98 (631.15) $16,713.20 (1,315.86) $14,482.45 (519.97) $13,865.48 (306.88) <0.0001
Pharmacy:
Infliximab $15,997.65 (413.51) $9,999.87 (293.82) $313.88 (175.79) $197.56 (53.23) <0.0001
Etanercept $101.26 (45.32) $178.18 (63.03) $10,426.90 (254.66) $10,099.71 (124.94)
Other $1,049.00 (69.20) $1,045.57 (145.45) $1,089.33 (88.71) $1,009.24 (48.61)
Total Pharmacy $17,147.90 (418.81) $11,223.62 (350.97) $11,830.12 (292.80) $11,306.51 (136.87)
Outpatient:
Management $635.68 (53.29) $766.75 (112.25) $377.98 (29.58) $382.19 (41.21)
Emergency Room $13.85 (4.11) $12.54 (6.32) $4.72 (1.81) $7.09 (1.76)
Ancillary $1,601.47 (116.33) $1,387.33 (118.42) $842.11 (122.13) $871.60 (90.63)
Total Outpatient $2,251.00 (136.95) $2,166.62 (176.82) $1,224.81 (135.67) $1,260.88 (120.64)
Hospitalization Costs $1,516.08 (393.06) $3,322.95 (1,191.16) $1,427.52 (411.72) $1,298.08 (249.13)
Non-RA Related Costs $5,370.17 (536.68) $6,104.37 (1,210.40) $3,954.81 (415.94) $4,177.57 (281.46) 0.0302
Grand Total $26,285.15 (1,022.19) $22,817.56 (2,431.57) $18,437.26 (809.69) $18,043.04 (496.95) <0.0001BMC Musculoskeletal Disorders 2004, 5:36 http://www.biomedcentral.com/1471-2474/5/36
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dose change for infliximab was based on two infusions
within seven weeks on two or more occasions. It is possi-
ble that some patients may have had these non-standard
queuing times simply as a result of scheduling availability,
and not as a result of dose escalation. Clear estimates of
dose increase due to increased frequency may only be
obtained through a more controlled observational study.
Furthermore, no information is available in this adminis-
trative database regarding the reason for dose escalation –
lack of efficacy, increase in symptoms, other reasons. Our
major focus for this study was therefore to simply docu-
ment that standard dosing assumptions regarding inflixi-
mab may lead to erroneous conclusions regarding its cost,
given the high level of escalation seen in this and other
studies. In addition, the database lacks clinical detail on
levels of disease severity as well as other potentially
important variables (e.g., working status) for considera-
tion of the full clinical and economic impact of dose
escalation.
As with all retrospective study, we cannot rule out the pos-
sibility that differences in disease progression and/or
severity between patients who do and do not escalate dose
may have influenced our findings. Nevertheless, our
results remained statistically significant even after control-
ling for observable differences between groups, indicating
that any selection bias would likely only affect the magni-
tude, not the direction, of our findings.
Finally, while the data used represent final, adjudicated
claims in a health plan setting, it is possible that the data
elements used are subject to coding or misclassification
error. Nevertheless, if such an error rate exists, it is likely
not a systematic phenomenon – that is, there is no reason
to expect that coding errors would disproportionately
affect the infliximab or etanercept samples in our study.
Conclusions
Despite the limitations noted above, we believe our study
has important implications. While, the results of recent
observational studies suggest that both infliximab and
etanercept are highly effective in clinical practice [17], our
findings suggest that patients with rheumatoid arthritis
who initiate infliximab therapy are much more likely to
experience an increase in dose over the course of one year
relative to patients who initiate etanercept. This increase
in dose leads to significantly higher pharmacy costs, as
well as increases in many other RA-related medical costs.
While there may be clinical factors in the decision to pick
one route of therapy administration over another, public
and private payers alike should carefully consider the eco-
nomic implications of coverage decisions when targeting
appropriate candidates for anti-TNF therapy.
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